Veracyte Says Data Shows Potential to Enhance Afirma Gene Expression Classifier Using RNA …

<!– Trending Stock News –> Veracyte (NASDAQ:VCYT), a molecular diagnostics company, reported Friday new data suggesting the potential to enhance the performance of the Afirma gene expression classifier (GEC) in thyroid cancer diagnosis by combining the test’s RNA expression-based capabilities with gene variant and fusion formation. In the study, researchers used RNA from thyroid nodule patient samples for which a surgical pathology diagnosis was known to train and test an enhanced version of the Afirma GEC. Using machine-learning techniques, Veracyte used an RNA sequencing platform to combine the genomic test’s RNA gene expression-based algorithm with gene variant and fusion information resulting in an enriched classifier that yielded an overall area under curve of 0.88, with a sensitivity of 93% and a specificity of 80%. “Numerous efforts have been made to…


Link to Full Article: Veracyte Says Data Shows Potential to Enhance Afirma Gene Expression Classifier Using RNA …